仁度生物：预计2025年年度净利润为720万元~1080万元

Group 1 - The company, Rendu Biotech, forecasts a net profit attributable to shareholders of 7.2 million to 10.8 million yuan for the fiscal year 2025, representing an increase of 15.01 million to 18.61 million yuan compared to the previous year, indicating a turnaround from losses to profits [1] - The primary reason for the performance change is the implementation of the "quality improvement and efficiency enhancement" action plan, which includes cost reduction and expense control measures, leading to a year-on-year decrease in period expenses [1] - During the reporting period, the company improved accounts receivable management, recovering some receivables from previous years and reversing part of the impairment losses [1] Group 2 - The nuclear power construction industry is experiencing a surge, with equipment manufacturers operating at full capacity, with orders scheduled until 2028, and employees working in three shifts, maintaining 24-hour production lines [1]